Affect Therapeutics

Evaluating Affect Therapeutics (Jacksonville, FL): The facility's programming is outpatient (IOP, MAT), not residential. The structural dimensions to verify — state licensure, voluntary accreditation, clinical-framework alignment with ASAM 4e — are each independently checkable and worth doing before admission rather than after.

Care levels at Affect Therapeutics

Affect Therapeutics is an outpatient-focused program (IOP, MAT) — patients live at home or in sober living and attend treatment sessions. This level of care is clinically appropriate for mild-to-moderate substance use disorder, or for patients stepping down from residential. ASAM Criteria 4e is the benchmark framework for matching patients to appropriate intensity. Most major payer medical-necessity documents reference it. An outside ASAM-aligned assessment, prior to admission, is the protection against misplacement.

Insurance and payment

Affect Therapeutics accepts both Medicaid and commercial insurance, which is the broadest payer profile and typically correlates with programs that operate at scale across the economic spectrum. Before admission, request a written Verification of Benefits from the facility's utilization-review team. Verbal VOB is where most post-admission cost-sharing disputes originate. Written documentation settles them.

Before you call

The operational due diligence on Affect Therapeutics comes down to three documents: ASAM-aligned level-of-care documentation matching independent clinical assessment, written Verification of Benefits for your specific plan product, written MAT policy. The facility's documented pharmacotherapy offerings suggest MAT is available — confirm the specific medications and prescriber access during the admissions conversation.